Cost-effectiveness analyses (CEAs) of genetic testing are increasing in frequency. Such analyses can inform providers, policy makers, and payers' coverage decisions.
and it is considered a tier 1 application that warrants population-level implementation. 10 However, effective interventions are not necessarily cost-effective. Severin et al. 5 constructed a detailed Markov CEA model and used it to evaluate several testing strategies for LS in the German health-care context. They concluded that routine testing was very unlikely to be cost-effective relative to family history-based testing using the Revised Bethesda Guidelines (RBG) and that even RBGbased testing was unlikely to be cost-effective. In this issue of Genetics in Medicine, Leenen et al. 6 modeled a similar range of testing strategies in the Dutch health-care context and concluded that testing of all CRC patients 70 years of age or younger is likely to be cost-effective relative to testing younger patients only and possibly cost-effective relative to RBG-based testing. Both studies included RBG-based testing as a comparison, unlike some CEAs that compared routine testing with no testing.
Rather than create their own epidemiologic model of disease incidence and the effectiveness of surveillance in preventing cancer and death, Leenen et al. 6 borrowed estimates of health gains per proband and per relative identified with LS from the literature and applied them to empirical estimates of testing costs and uptake in the Netherlands . That modeling approach has the advantage of simplicity and can facilitate comparisons with findings of previous CEA studies. However, it leaves the epidemiologic assumptions that underpin estimates of effectiveness and cost-effectiveness inside an unexamined "black box. " Key parameters that can influence estimates of health gains resulting from identification of LS carriers include the following:
• Number of relatives tested per index case • Uptake and adherence to intensive colonoscopic surveillance by relatives • Age-specific incidence of CRC among carriers and the general population Leenen et al. conducted sensitivity analyses that revealed that the most influential parameter in their cost-effectiveness model is the gain in life expectancy per mutation-carrying relative detected. They varied this parameter within the range of published estimates and concluded that in most cases, the ICER is less than €40,000 per LYG, which they considered a measure of cost-effectiveness in the Netherlands.
It is important to take a close look at the plausibility of the epidemiologic assumptions that underlie the published estimates of health gains from intensive surveillance of carriers. Leenen et al. cite published estimates from 11 studies ranging from 0.50 to 32.76 LYG per relative. Part of that range is explained by mixing together discounted and undiscounted life expectancy; when a 3% discount rate is applied, the range is from 0.50 to 20.97. The higher estimates come from studies that were published before much was known about the epidemiology of LS. Among studies published since 2011, the highest estimate of 8.20 LYG per relative (reported in the text as 6.9-7.2 LYG per relative) came from a Dutch modeling study. 11 That study assumed 3.5% annual incidence of CRC among mutation carriers, which is much higher than is consistent with epidemiologic estimates of age-specific CRC annual incidence among mutation carriers (0.3 to 1.5%). 5, 12 Consequently, that study may not be a reasonable basis for comparison of the cost-effectiveness of testing for LS.
The three other recent estimates cited by Leenen et al. ranged from 0.50 to 0.68 LYG per relative. Ladabaum et al. 13 and Severin et al. 5 projected that routine testing relative to no testing would add 0.50 and 0.52 discounted LYG per mutation-carrying relative, respectively. Despite the similarity of those estimates, the two studies adopted different assumptions, including the choice of discount rates (3.5 and 3.0%, respectively). 2 The cumulative incidence of CRC until age 70 was assumed by Severin et al. to be 35% and by Ladabaum et al. to be 50%; other authors have concluded that a cumulative incidence of 35% appears to be the best estimate. 14 7 One potential explanation for the difference in estimates of health impact is that Mvundura et al. used a static model instead of the Markov state-transition models used by recent studies. 5, 13 An important implication is that the most informative costeffectiveness estimates are likely to be based on fully specified state-transition models of disease incidence and progression informed by epidemiologic estimates from studies in which various sources of bias have been minimized.
Leenen et al. contend that their results are "very conservative" because their assumption of health gains is at the low end of the range of published estimates. However, the likely range of estimates of health gains from routine LS testing based on statetransition models is 0.5-0.6 LYG per mutation-carrying relative identified. Higher estimates of health gains from identifying LS mutation carriers may not be consistent with the best available epidemiologic evidence or based on recommended modeling techniques. Consequently, although the point estimates reported by Leenen et al. appear reasonable, uncertainty regarding those estimates remains. Consequently, whether testing meets the €40,000 per LYG criterion of cost-effectiveness may still be questioned and it is still unclear what cost-effectiveness criterion, if any, is used by decision makers in the Netherlands.
In addition, whether LS testing is considered cost-effective in a particular setting depends on additional factors such as the number of relatives per index case and the proportion of relatives who are tested, as well as the costs of genetic counseling.
Leenen et al. made an important contribution by integrating cost-effectiveness estimates with a population-based cohort study of routine LS testing that included empirical data regarding both the numbers of relatives tested and detected with mutations and the costs associated with such testing. 6 Routine LS testing in CRC patients up to age 70 years is probably cost-effective relative to no screening, at least in some settings, and may even be cost-effective relative to RBG-based testing. Definitive conclusions about the cost-effectiveness of genetic tests for LS and other diseases in a given setting require a fully specified model of health outcomes resulting from the detection of carriers that is based on the best available epidemiologic estimates.
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